FFA
TXMD icon

Farther Finance Advisors’s TherapeuticsMD TXMD Stock Holding History

Farther Finance Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86 Buy
39
+8
+26% +$17 ﹤0.01% 5805
2026
Q1 		$62 Buy
31
+1
+3% +$2 ﹤0.01% 5558
2025
Q4 		$49 Hold
30
– – ﹤0.01% 5355
2025
Q3 		$32 Hold
30
– – ﹤0.01% 4890
2025
Q2 		$35 Hold
30
– – ﹤0.01% 4396
2025
Q1 		$29 Buy
+30
New +$30 ﹤0.01% 4170

Other funds holding TXMD

SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
PWA
Provenance Wealth Advisors Fort Lauderdale, Florida $1.05B AUM 18.67% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
SWIM
Smallwood Wealth Investment Management Red Bank, New Jersey $229M AUM 23.56% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Farther Finance Advisors's TXMD Position: Q2 2026 in Review

Farther Finance Advisors increased its TherapeuticsMD (TXMD) stake by 26% in Q2 2026, buying an estimated $17 and bringing the position to 39 shares worth $86. The position accounts for ﹤0.01% of the portfolio, ranked #5805.

Farther Finance Advisors first reported a position in TXMD in Q1 2025 and has held it in 6 quarters since. 9 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Farther Finance Advisors held 39 shares of TherapeuticsMD worth $86 as of Q2 2026.
  • Farther Finance Advisors bought 8 TherapeuticsMD shares in Q2 2026, an estimated $17.
  • TherapeuticsMD made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5805 holding.
  • Farther Finance Advisors first reported a position in TherapeuticsMD in Q1 2025 and has held it in 6 quarters since.
  • 9 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.